Haemophilus infectious disease

Summary

Haemophilus infectious disease (MONDO:0006926) is a disease and 12 clinical trials. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	haemophilus infectious disease
Mondo ID	MONDO:0006926
EFO	EFO:1001127
MeSH	D006192
NCIT	C34654
SNOMED CT	41659003
Is cancer (heuristic)	no

Also known as: Haemophilus caused disease or disorder · Haemophilus disease or disorder · Haemophilus infection · Haemophilus infectious disease · haemophilus infectious disease · Hemophilus infection · Hemophilus infections · infection, Haemophilus · infection, Hemophilus · infections, Haemophilus · infections, Hemophilus

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › haemophilus infectious disease

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (2): haemophilus meningitis, chancroid

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	6
PHASE4	3
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00255021	PHASE4	COMPLETED	Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand
NCT00802867	PHASE4	COMPLETED	Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
NCT01357720	PHASE4	COMPLETED	Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination
NCT00254969	PHASE3	COMPLETED	Immunogenicity and Safety of Pentaxim in South African Infants
NCT00259337	PHASE3	COMPLETED	Immunogenicity and Safety of Pentaxim™ in an Indian Population
NCT00343889	PHASE3	COMPLETED	Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
NCT00432042	PHASE3	COMPLETED	Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
NCT00772928	PHASE3	COMPLETED	Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
NCT01917357	PHASE3	COMPLETED	A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
NCT00625118	Not specified	COMPLETED	A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years
NCT00772369	Not specified	COMPLETED	Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
NCT00855855	Not specified	COMPLETED	Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease